Nu-Sucralfate

Nu-Sucralfate may be available in the countries listed below.

Ingredient matches for Nu-Sucralfate

Sucralfate

Sucralfate is reported as an ingredient of Nu-Sucralfate in the following countries:

• Canada

International Drug Name Search

Ketopain

Ketopain may be available in the countries listed below.

Ingredient matches for Ketopain

Ketorolac

Ketorolac tromethamine (a derivative of Ketorolac) is reported as an ingredient of Ketopain in the following countries:

• Indonesia

International Drug Name Search

Diclohexal

Diclohexal may be available in the countries listed below.

Ingredient matches for Diclohexal

Diclofenac

Diclofenac sodium salt (a derivative of Diclofenac) is reported as an ingredient of Diclohexal in the following countries:

• Australia


• South Africa

International Drug Name Search

Famvir

Famvir is a brand name of famciclovir, approved by the FDA in the following formulation(s):

FAMVIR (famciclovir - tablet; oral)

• 
  Manufacturer: NOVARTIS
  
  Approval date: June 29, 1994
  
  Strength(s): 500MG ^[RLD][AB]


• 
  Manufacturer: NOVARTIS
  
  Approval date: December 11, 1995
  
  Strength(s): 125MG ^[AB]


• 
  Manufacturer: NOVARTIS
  
  Approval date: April 26, 1996
  
  Strength(s): 250MG ^[AB]

Has a generic version of Famvir been approved?

A generic version of Famvir has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Famvir and have been approved by the FDA:

famciclovir tablet; oral

• 
  Manufacturer: APOTEX
  
  Approval date: July 22, 2011
  
  Strength(s): 125MG ^[AB], 250MG ^[AB], 500MG ^[AB]


• 
  Manufacturer: AUROBINDO PHARMA LTD
  
  Approval date: March 21, 2011
  
  Strength(s): 125MG ^[AB], 250MG ^[AB], 500MG ^[AB]


• 
  Manufacturer: MACLEODS PHARMS LTD
  
  Approval date: January 12, 2012
  
  Strength(s): 125MG ^[AB], 250MG ^[AB], 500MG ^[AB]


• 
  Manufacturer: MYLAN
  
  Approval date: March 24, 2011
  
  Strength(s): 125MG ^[AB], 250MG ^[AB], 500MG ^[AB]


• 
  Manufacturer: ROXANE
  
  Approval date: March 21, 2011
  
  Strength(s): 125MG ^[AB], 250MG ^[AB], 500MG ^[AB]


• 
  Manufacturer: TEVA PHARMS
  
  Approval date: August 24, 2007
  
  Strength(s): 125MG ^[AB], 250MG ^[AB], 500MG ^[AB]


• 
  Manufacturer: WATSON LABS
  
  Approval date: March 21, 2011
  
  Strength(s): 125MG ^[AB], 250MG ^[AB], 500MG ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Famvir. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Treatment of a latent infection of herpes viruses
  Patent 5,840,763
  Issued: November 24, 1998
  Inventor(s): Field; Hugh John & Thackray; Alana Maureen & Bacon; Teresa Helen & Sutton; David & Vere Hodge; Richard Anthony
  Assignee(s): SmithKline Beecham plc
  A method for the treatment of latent infection of herpesviruses in mammals, including humans, which method comprises administering to the mammal in need of such treatment, an effective amount of a compound of formula (A): ##STR1## or a bioprecursor, or a pharmaceutically acceptable salt, phosphate ester and/or acyl derivative of either of the foregoing.
  
  Patent expiration dates:
  
  
  • September 1, 2015
    
    ✓ 
    Patent use: METHOD OF TREATING VARICELLA ZOSTER (SHINGLES) INFECTIONS
  
  
  
  • March 1, 2016
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Penciclovir for the treatment of post therapeutic neuralgia
  Patent 5,866,581
  Issued: February 2, 1999
  Inventor(s): Boon; Ronald James & Griffin; David Ronald John
  Assignee(s): SmithKline Beecham p.l.c.
  A method for the treatment of PHN in mammals, including humans, which method comprises administering an effective amount of a compound of formula (A), or a pharmaceutically acceptable salt thereof. ##STR1##
  
  Patent expiration dates:
  
  
  • October 4, 2014
    
    ✓ 
    Patent use: METHOD OF TREATING VARICELLA ZOSTER (SHINGLES) INFECTIONS
  
  
  
  • April 4, 2015
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Treatment of a latent infection of herpes virus
  Patent 5,916,893
  Issued: June 29, 1999
  Inventor(s): Field; Hugh John & Thackray; Alana Maureen & Bacon; Teresa Helen & Sutton; David & Vere Hodge; Richard Anthony
  Assignee(s): SmithKline Beecham p.l.c.
  A method for the treatment of latent infection of herpesviruses in mammals, including humans, which method comprises administering to the mammal in need of such treatment, an effective amount of a compound of formula (A): ##STR1## or a bioprecursor, or a pharmaceutically acceptable salt, phosphate ester and/or acyl derivative of either of the foregoing.
  
  Patent expiration dates:
  
  
  • September 1, 2015
    
    ✓ 
    Patent use: METHOD OF TREATING VARICELLA ZOSTER (SHINGLES) INFECTIONS
  
  
  
  • March 1, 2016
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Penciclovir for the treatment of zoster associated pain
  Patent 6,124,304
  Issued: September 26, 2000
  Inventor(s): Boon; Ronald James & Griffin; David Ronald John
  Assignee(s): SmithKline Beecham PLC
  A method for the treatment of ZAP, in particular PHN, in mammals, including humans, which method comprises administering to the mammal in need of such treatment, an effective amount of penciclovir or famciclovir, or a pharmaceutically acceptable salt thereof.
  
  Patent expiration dates:
  
  
  • October 4, 2014
    
    ✓ 
    Patent use: METHOD OF TREATING VARICELLA ZOSTER (SHINGLES) INFECTIONS
  
  
  
  • April 4, 2015
    
    ✓ 
    Pediatric exclusivity
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • December 24, 2012 - INFORMATION FROM PEDIATRIC STUDIES ADDED TO LABEL
  
  
  • June 24, 2013 - PEDIATRIC EXCLUSIVITY
  
  
  • January 31, 2014 - NEW INFORMATION FROM A STUDY WHICH EVALUATED THE SAFETY AND EFFICACY OF FAMVIR IN TREATING RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT BLACK/AFRICAN AMERICAN SUBJECTS.
  
  

See also...

• Famvir Consumer Information (Drugs.com)
• Famvir Consumer Information (Wolters Kluwer)
• Famvir Consumer Information (Cerner Multum)
• Famvir Advanced Consumer Information (Micromedex)
• Famvir AHFS DI Monographs (ASHP)
• Famciclovir Consumer Information (Wolters Kluwer)
• Famciclovir Consumer Information (Cerner Multum)
• Famciclovir Advanced Consumer Information (Micromedex)
• Famciclovir AHFS DI Monographs (ASHP)

Alopam

Alopam may be available in the countries listed below.

Ingredient matches for Alopam

Oxazepam

Oxazepam is reported as an ingredient of Alopam in the following countries:

• Denmark


• Norway

International Drug Name Search

Detrusan

Detrusan may be available in the countries listed below.

Ingredient matches for Detrusan

Oxybutynin

Oxybutynin hydrochloride (a derivative of Oxybutynin) is reported as an ingredient of Detrusan in the following countries:

• Austria

International Drug Name Search

Ethambutolo

Ethambutolo may be available in the countries listed below.

Ingredient matches for Ethambutolo

Ethambutol

Ethambutolo (DCIT) is known as Ethambutol in the US.

International Drug Name Search

Glossary

DCIT	Denominazione Comune Italiana

Click for further information on drug naming conventions and International Nonproprietary Names.